Last reviewed · How we verify

NCT06627621

E-Polycaprolactone-Containing Membrane in Alveolar Bone Regeneration

Completed EARLY_PHASE1 Last updated 4 October 2024
What this trial tests

EARLY_PHASE1 trial testing Alveolar Ridge Reconstruction in Alveolar Bone Grafting in 4 participants. Completed in 8 January 2023.

Timeline
8 March 2021
Primary endpoint
8 January 2023
8 January 2023

Quick facts

Lead sponsorcem üngör
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment4
Start date8 March 2021
Primary completion8 January 2023
Estimated completion8 January 2023
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

cem üngör

Who can join

Adults 18 Months to 80 Months, any sex, with Alveolar Bone Grafting. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to evaluate the effectiveness of synthetic polycaprolactone (PCL) bioscaffold membranes used for alveolar augmentation in maxillofacial surgery for increasing the amount of newly formed bone after three-dimensional application.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Alveolar Ridge Reconstruction

Trials testing the same drug.

Other recruiting trials for Alveolar Bone Grafting

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06627621.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing